Yulong He

机构：Qinghai University, Sun Yat-sen University, Anhui Medical University, Sichuan University, West China Hospital of Sichuan University, Jiuquan Iron & Steel (China), The Seventh Affiliated Hospital of Sun Yat-sen University, The First Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Anhui Medical University · ORCID：0000-0001-8930-8404

发表论文 70 篇 · 总被引 1454 次 · h-index 20

代表论文

• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial (2021 · The Lancet Oncology · 被引 446)
• Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial (2025 · The Lancet Oncology · 被引 53)
• Methods for conducting international Delphi surveys to optimise global participation in core outcome set development: a case study in gastric cancer informed by a comprehensive literature review (2021 · Trials · 被引 47)
• The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial (2021 · BMC Cancer · 被引 38)
• Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial (2024 · Journal of Hematology & Oncology · 被引 35)
• The Prognostic Effect of Multidisciplinary Team Intervention in Patients with Advanced Gastric Cancer (2022 · Current Oncology · 被引 27)